( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study.
In the present nonr and omized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole ( 0.25 mg anastrozole/d for 6 months ) in the treatment of women with histologically proven rectovaginal endometriosis . In a series of 10 patients , dysmenorrhea , physical and social functioning , but not chronic pelvic pain and dyspareunia , improved during therapy
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .